The company is commercializing novel instrumentation and services for rapidly and comprehensively conducting high-throughput nucleotide sequencing, with specific application to the sequencing of whole genomes and ultra-deep sequencing of target genes.
Advancell is active in nanomedicine. The company has two divisions: Pharma, which focuses its activity on the development of innovative drugs through the search for new applications for already-known molecules, and Services and Reagents, which uses cell-based in vitro methods to predict the efficacy, safety and mechanism of action of developing molecules.
The Ambion brand encompasses a complete range of products for researchers whose work involves RNA. These include products for the isolation, detection, quantification, amplification, and characterization of RNA.
The company's technology is based on the large scale production of nanometric particles known as VLPs (virus like particles). The most advanced application of this technology is the production of viral vector derived vaccines for human and animal health.
Blend Therapeutics is a biopharmaceutical company discovering new classes of medicines to treat debilitating diseases. The company is pioneering an integrative way to discover molecular entities with new mechanisms of action purposely designed for our proprietary nanoparticles. By synergistically developing both the molecule and the nanoparticle together they can make medicines more targeted, more effective and more tolerable.
Calevia aims to harness the power of molecular targeting technologies and the heat-generation capacity of MesoGraf Xide, a photo-responsive graphene material, to create bio-conjugates designed to home-in on - and destroy - cancer cells in a non-invasive, non-pharmacological and efficient manner.
Celera has a successful molecular diagnostics business and powerful genomic and proteomic discovery platforms that have identified and validated new drug targets and biomarkers that will advance the practice of Targeted Medicine.
Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
One of the world's foremost biotechnology companies, the company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing.
(German language site) The company is a Contract Research Organisation for the development and improvement of advanced cell culture systems for industrial drug screening applications, biomaterial testing and pharma-toxicological research.
The company specializes in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using their proprietary technology.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.